购物车
- 全部删除
- 您的购物车当前为空
PF-4708671 是一种可渗透细胞的 p70 核糖体 S6 激酶抑制剂,对 S6K1的Ki 为 20 nM,IC50为 160 nM。
为众多的药物研发团队赋能,
让新药发现更简单!
PF-4708671 是一种可渗透细胞的 p70 核糖体 S6 激酶抑制剂,对 S6K1的Ki 为 20 nM,IC50为 160 nM。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
5 mg | ¥ 298 | 现货 | |
10 mg | ¥ 491 | 现货 | |
25 mg | ¥ 961 | 现货 | |
50 mg | ¥ 1,637 | 现货 | |
100 mg | ¥ 2,767 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 539 | 现货 |
产品描述 | PF-4708671 is a cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform) .In cell-free assays, PF-4708671(PF4708671) is potent for S6K1(Ki50=20 nM, IC50=160 nM). |
靶点活性 | p70 S6K1:160 nM |
体内活性 | PF-4708671可抑制S6K1介导的S6蛋白对IGF-1(胰岛素样生长因子1)的磷酸化反应,还能够通过mTORC1(mTOR复合物1)诱导S6K1的T环和疏水基序的磷酸化。 |
激酶实验 | Affinity determination: Purified activated FAK kinase domain (amino acids 410–689) is reacted with 50 μM ATP, and 10 μg/well of a random peptide polymer of Glu and Tyr (molar ratio of 4:1), poly(Glu/Tyr) in kinase buffer (50 mM HEPES, pH 7.5, 125 mM NaCl, 48 mM MgCl2) for 15 min. Phosphorylation of poly(Glu/Tyr) is challenged with serially diluted compounds at 1/2-Log concentrations starting at a top concentration of 1 μM. Each concentration is run in triplicate. Phosphorylation of poly(Glu/Tyr) is detected with a general anti-phospho-tyrosine (PY20) antibody, followed by horseradish peroxidase-conjugated goat anti-mouse IgG antibody. The standard horseradish peroxidase substrate 3, 3', 5, 5'-tetramethylbenzidine is added, and Optical Density readings at 450 nm are obtained following the addition of stop solution (2 M H2SO4). The IC50 values are determined using the Hill slope model. |
别名 | PF4708671 |
分子量 | 390.41 |
分子式 | C19H21F3N6 |
CAS No. | 1255517-76-0 |
Smiles | CCc1cncnc1N1CCN(Cc2nc3cc(ccc3[nH]2)C(F)(F)F)CC1 |
密度 | 1.348 g/cm3 (Predicted) |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 19.5 mg/mL (50 mM) Ethanol: 19.5 mg/mL (50 mM) | ||||||||||||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||||||||||||
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容